| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5584409 | Experimental and Molecular Pathology | 2017 | 8 Pages |
Abstract
ERCC1 expression levels may help in selecting patients who benefit from oxaliplatin chemotherapy in stage III & IV CRC. Further large trials are needed to validate these data.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Amira B. Kassem, Salem Eid Salem, Mohamed E. Abdelrahim, Amira S.A. Said, Ahmad Salahuddin, Marwa Mahmoud Hussein, Abeer A. Bahnassy,